Jin-Feng Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jin-Feng Zhao has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ian G. Ganley
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA
3 shared publications - Gopal P. Sapkota
University of Dundee
2 shared publications - Alan R. Prescott
Dundee Imaging Facility, School of Life Sciences, University of Dundee
1 shared publication - Brendan M. Corcoran
The University of Edinburgh
1 shared publication - Conchita Fraguas Bringas
University of Copenhagen
1 shared publication - Florentina Negoita
University of Copenhagen
1 shared publication
Latest Publications
- Open Access
- 19 November 2026
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 483 (12) , 2409-2434
Targeted modulation of protein post-translational modifications through induced proximity: advances and practical toolkits
Targeted post-translational modification (PTM) of a protein of interest (POI) is achieved by inducing proximity to a protein-modifying effector enzyme in cells. A number of distinct induced proximity modalities, including genetically encodable polypeptides, small heterobifunctional molecules and molecular glues, can be applied to induce proximity between virtually any two intracellular proteins. Because targeted PTM can alter protein function and fate, induced proximity offers a route to target many proteins previously considered undruggable. With several molecular glue degraders long employed in clinic and one proteolysis-targeting chimera (PROTAC) recently FDA-approved for clinical use, induced proximity modality has emerged as clinically validated and rapidly expanding avenue for drug discovery. Beyond therapeutic applications, targeted PTM provides a versatile experimental platform for dissecting the functions and consequences of specific PTMs in physiological and disease contexts. In this review, we present an up-to-date overview of advances in targeted modulation of protein PTMs using induced-proximity technologies. We also highlight several induced-proximity toolkits and include practical information on them to facilitate their rapid adoption for proof-of-concept studies on targeted modulation of PTMs in cells.
- 19 November 2026
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 483 (12) , 2409-2434
Open AccessTargeted modulation of protein post-translational modifications through induced proximity: advances and practical toolkits
Targeted post-translational modification (PTM) of a protein of interest (POI) is achieved by inducing proximity to a protein-modifying effector enzyme in cells. A number of distinct induced proximity modalities, including genetically encodable polypeptides, small heterobifunctional molecules and molecular glues, can be applied to induce proximity between virtually any two intracellular proteins. Because targeted PTM can alter protein function and fate, induced proximity offers a route to target many proteins previously considered undruggable. With several molecular glue degraders long employed in clinic and one proteolysis-targeting chimera (PROTAC) recently FDA-approved for clinical use, induced proximity modality has emerged as clinically validated and rapidly expanding avenue for drug discovery. Beyond therapeutic applications, targeted PTM provides a versatile experimental platform for dissecting the functions and consequences of specific PTMs in physiological and disease contexts. In this review, we present an up-to-date overview of advances in targeted modulation of protein PTMs using induced-proximity technologies. We also highlight several induced-proximity toolkits and include practical information on them to facilitate their rapid adoption for proof-of-concept studies on targeted modulation of PTMs in cells.
- Open Access
- 23 February 2026
- Published by Taylor & Francis in Autophagy
- Vol. 22 (6) , 1386-1400
AMPK promotes TFEB transcriptional activity through dephosphorylation at both MTORC1-dependent and -independent sites
TFEB (transcription factor EB) and related TFE3 (transcription factor binding to IGHM enhancer 3) are members of the basic helix-loop-helix leucine zipper family of transcription factors [1]. TFEB ...
- 23 February 2026
- Published by Taylor & Francis in Autophagy
- Vol. 22 (6) , 1386-1400
Open AccessAMPK promotes TFEB transcriptional activity through dephosphorylation at both MTORC1-dependent and -independent sites
TFEB (transcription factor EB) and related TFE3 (transcription factor binding to IGHM enhancer 3) are members of the basic helix-loop-helix leucine zipper family of transcription factors [1]. TFEB ...
- Open Access
- 11 March 2024
- Published by Taylor & Francis in Autophagy Reports
- Vol. 3 (1) , 2326402
PINK1 regulated mitophagy is evident in skeletal muscles
PINK1, mutated in familial forms of Parkinson's disease, initiates mitophagy following mitochondrial depolarization. However, it is difficult to monitor this pathway physiologically in mice as loss of PINK1 does not alter basal mitophagy levels in most tissues. To further characterize this pathway in vivo, we used mito-QC mice in which loss of PINK1 was combined with the mitochondrial-associated POLGD257A mutation. We focused on skeletal muscle as gene expression data indicates that this tissue has the highest PINK1 levels. We found that loss of PINK1 in oxidative hindlimb muscle significantly reduced mitophagy. Of interest, the presence of the POLGD257A mutation, while having a minor effect in most tissues, restored levels of muscle mitophagy caused by the loss of PINK1. Although our observations highlight that multiple mitophagy pathways operate within a single tissue, we identify skeletal muscle as a tissue of choice for the study of PINK1-dependant mitophagy under basal conditions.
- 11 March 2024
- Published by Taylor & Francis in Autophagy Reports
- Vol. 3 (1) , 2326402
Open AccessPINK1 regulated mitophagy is evident in skeletal muscles
PINK1, mutated in familial forms of Parkinson's disease, initiates mitophagy following mitochondrial depolarization. However, it is difficult to monitor this pathway physiologically in mice as loss of PINK1 does not alter basal mitophagy levels in most tissues. To further characterize this pathway in vivo, we used mito-QC mice in which loss of PINK1 was combined with the mitochondrial-associated POLGD257A mutation. We focused on skeletal muscle as gene expression data indicates that this tissue has the highest PINK1 levels. We found that loss of PINK1 in oxidative hindlimb muscle significantly reduced mitophagy. Of interest, the presence of the POLGD257A mutation, while having a minor effect in most tissues, restored levels of muscle mitophagy caused by the loss of PINK1. Although our observations highlight that multiple mitophagy pathways operate within a single tissue, we identify skeletal muscle as a tissue of choice for the study of PINK1-dependant mitophagy under basal conditions.
- Open Access
- 13 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1643
p53 Regulates Mitochondrial Dynamics in Vascular Smooth Muscle Cell Calcification
Arterial calcification is an important characteristic of cardiovascular disease. It has key parallels with skeletal mineralization; however, the underlying cellular mechanisms responsible are not fully understood. Mitochondrial dynamics regulate both bone and vascular function. In this study, we therefore examined mitochondrial function in vascular smooth muscle cell (VSMC) calcification. Phosphate (Pi)-induced VSMC calcification was associated with elongated mitochondria (1.6-fold increase, p < 0.001), increased mitochondrial reactive oxygen species (ROS) production (1.83-fold increase, p < 0.001) and reduced mitophagy (9.6-fold decrease, p < 0.01). An increase in protein expression of optic atrophy protein 1 (OPA1; 2.1-fold increase, p < 0.05) and a converse decrease in expression of dynamin-related protein 1 (DRP1; 1.5-fold decrease, p < 0.05), two crucial proteins required for the mitochondrial fusion and fission process, respectively, were noted. Furthermore, the phosphorylation of DRP1 Ser637 was increased in the cytoplasm of calcified VSMCs (5.50-fold increase), suppressing mitochondrial translocation of DRP1. Additionally, calcified VSMCs showed enhanced expression of p53 (2.5-fold increase, p < 0.05) and β-galactosidase activity (1.8-fold increase, p < 0.001), the cellular senescence markers. siRNA-mediated p53 knockdown reduced calcium deposition (8.1-fold decrease, p < 0.01), mitochondrial length (3.0-fold decrease, p < 0.001) and β-galactosidase activity (2.6-fold decrease, p < 0.001), with concomitant mitophagy induction (3.1-fold increase, p < 0.05). Reduced OPA1 (4.1-fold decrease, p < 0.05) and increased DRP1 protein expression (2.6-fold increase, p < 0.05) with decreased phosphorylation of DRP1 Ser637 (3.20-fold decrease, p < 0.001) was also observed upon p53 knockdown in calcifying VSMCs. In summary, we demonstrate that VSMC calcification promotes notable mitochondrial elongation and cellular senescence via DRP1 phosphorylation. Furthermore, our work indicates that p53-induced mitochondrial fusion underpins cellular senescence by reducing mitochondrial function.
- 13 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1643
Open Accessp53 Regulates Mitochondrial Dynamics in Vascular Smooth Muscle Cell Calcification
Arterial calcification is an important characteristic of cardiovascular disease. It has key parallels with skeletal mineralization; however, the underlying cellular mechanisms responsible are not fully understood. Mitochondrial dynamics regulate both bone and vascular function. In this study, we therefore examined mitochondrial function in vascular smooth muscle cell (VSMC) calcification. Phosphate (Pi)-induced VSMC calcification was associated with elongated mitochondria (1.6-fold increase, p < 0.001), increased mitochondrial reactive oxygen species (ROS) production (1.83-fold increase, p < 0.001) and reduced mitophagy (9.6-fold decrease, p < 0.01). An increase in protein expression of optic atrophy protein 1 (OPA1; 2.1-fold increase, p < 0.05) and a converse decrease in expression of dynamin-related protein 1 (DRP1; 1.5-fold decrease, p < 0.05), two crucial proteins required for the mitochondrial fusion and fission process, respectively, were noted. Furthermore, the phosphorylation of DRP1 Ser637 was increased in the cytoplasm of calcified VSMCs (5.50-fold increase), suppressing mitochondrial translocation of DRP1. Additionally, calcified VSMCs showed enhanced expression of p53 (2.5-fold increase, p < 0.05) and β-galactosidase activity (1.8-fold increase, p < 0.001), the cellular senescence markers. siRNA-mediated p53 knockdown reduced calcium deposition (8.1-fold decrease, p < 0.01), mitochondrial length (3.0-fold decrease, p < 0.001) and β-galactosidase activity (2.6-fold decrease, p < 0.001), with concomitant mitophagy induction (3.1-fold increase, p < 0.05). Reduced OPA1 (4.1-fold decrease, p < 0.05) and increased DRP1 protein expression (2.6-fold increase, p < 0.05) with decreased phosphorylation of DRP1 Ser637 (3.20-fold decrease, p < 0.001) was also observed upon p53 knockdown in calcifying VSMCs. In summary, we demonstrate that VSMC calcification promotes notable mitochondrial elongation and cellular senescence via DRP1 phosphorylation. Furthermore, our work indicates that p53-induced mitochondrial fusion underpins cellular senescence by reducing mitochondrial function.
- Open Access
- 1 January 2013
- Published by Wiley in Mediators of Inflammation
- Vol. 2013, 1-14
Activation of TRPV1 Prevents OxLDL-Induced Lipid Accumulation and TNF-α-Induced Inflammation in Macrophages: Role of Liver X Receptorα
The transient receptor potential vanilloid type 1 (TRPV1) is crucial in the pathogenesis of atherosclerosis; yet its role and underlying mechanism in the formation of macrophage foam cells remain unclear. Here, we show increased TRPV1 expression in the area of foamy macrophages in atherosclerotic aortas of apolipoprotein E-deficient mice. Exposure of mouse bone-marrow-derived macrophages to oxidized low-density lipoprotein (oxLDL) upregulated the expression of TRPV1. In addition, oxLDL activated TRPV1 and elicited calcium (Ca2+) influx, which were abrogated by the pharmacological TRPV1 antagonist capsazepine. Furthermore, oxLDL-induced lipid accumulation in macrophages was ameliorated by TRPV1 agonists but exacerbated by TRPV1 antagonist. Treatment with TRPV1 agonists did not affect the internalization of oxLDL but promoted cholesterol efflux by upregulating the efflux ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. Moreover, the upregulation of ABC transporters was mainly through liver X receptorα- (LXRα-) dependent regulation of transcription. Moreover, the TNF-α-induced inflammatory response was alleviated by TRPV1 agonists but aggravated by the TRPV1 antagonist and LXRαsiRNA in macrophages. Our data suggest that LXRαplays a pivotal role in TRPV1-activation-conferred protection against oxLDL-induced lipid accumulation and TNF-α-induced inflammation in macrophages.
- 1 January 2013
- Published by Wiley in Mediators of Inflammation
- Vol. 2013, 1-14
Open AccessActivation of TRPV1 Prevents OxLDL-Induced Lipid Accumulation and TNF-α-Induced Inflammation in Macrophages: Role of Liver X Receptorα
The transient receptor potential vanilloid type 1 (TRPV1) is crucial in the pathogenesis of atherosclerosis; yet its role and underlying mechanism in the formation of macrophage foam cells remain unclear. Here, we show increased TRPV1 expression in the area of foamy macrophages in atherosclerotic aortas of apolipoprotein E-deficient mice. Exposure of mouse bone-marrow-derived macrophages to oxidized low-density lipoprotein (oxLDL) upregulated the expression of TRPV1. In addition, oxLDL activated TRPV1 and elicited calcium (Ca2+) influx, which were abrogated by the pharmacological TRPV1 antagonist capsazepine. Furthermore, oxLDL-induced lipid accumulation in macrophages was ameliorated by TRPV1 agonists but exacerbated by TRPV1 antagonist. Treatment with TRPV1 agonists did not affect the internalization of oxLDL but promoted cholesterol efflux by upregulating the efflux ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. Moreover, the upregulation of ABC transporters was mainly through liver X receptorα- (LXRα-) dependent regulation of transcription. Moreover, the TNF-α-induced inflammatory response was alleviated by TRPV1 agonists but aggravated by the TRPV1 antagonist and LXRαsiRNA in macrophages. Our data suggest that LXRαplays a pivotal role in TRPV1-activation-conferred protection against oxLDL-induced lipid accumulation and TNF-α-induced inflammation in macrophages.